Amgen Inc. (AMGN): Price and Financial Metrics
Amgen Inc. (AMGN)
Today's Latest Price: $224.13 USD
Updated May 28 6:55pm
Add AMGN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
AMGN Stock Summary
- AMGN has a market capitalization of $131,843,889,538 -- more than approximately 98.81% of US stocks.
- AMGN's went public 34.43 years ago, making it older than 92.87% of listed US stocks we're tracking.
- In terms of volatility of its share price, AMGN is more volatile than merely 4.09% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to Amgen Inc are ABBV, AZN, LLY, SNY, and BMY.
- AMGN's SEC filings can be seen here. And to visit Amgen Inc's official web site, go to www.amgen.com.
AMGN Stock Price Chart More Charts
AMGN Price/Volume Stats
| Current price | $224.13 | 52-week high | $244.99 |
| Prev. close | $224.81 | 52-week low | $166.68 |
| Day low | $222.25 | Volume | 2,591,000 |
| Day high | $226.62 | Avg. volume | 3,082,661 |
| 50-day MA | $222.27 | Dividend yield | 2.86% |
| 200-day MA | $218.03 | Market Cap | 131.84B |
Amgen Inc. (AMGN) Company Bio
Amgen discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company was founded in 1980 and is based in Thousand Oaks, California.
AMGN Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $224.13 | $192.08 | -15% |
Below please find a table outlining a discounted cash flow forecast for AMGN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Amgen Inc ranked in the 44th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Amgen Inc, consider:
- AMGN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 27.38% of tickers in our DCF set.
- The weighted average cost of capital for the company is 7. This value is greater than only 13.48% stocks in the Healthcare sector that generate free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -16% |
| 1% | -15% |
| 2% | -15% |
| 3% | -14% |
| 4% | -13% |
| 5% | -12% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as AMGN, try FONR, HNGR, CRL, DGX, and STE.
Loading social stream, please wait...